Ohr Pharmaceutical Inc. (NASDAQ:OHRP) Given $14.00 Consensus Target Price by Brokerages
Ohr Pharmaceutical Inc. (NASDAQ:OHRP) has received an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company. Ohr Pharmaceutical’s rating score has declined by 67% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a one year consensus target price of $14.00 for the company and are predicting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also given Ohr Pharmaceutical an industry rank of 93 out of 265 based on the ratings given to related companies.
A number of equities research analysts recently commented on OHRP shares. Zacks Investment Research lowered Ohr Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, July 30th. Brean Capital lowered Ohr Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Finally, Roth Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Ohr Pharmaceutical in a research report on Thursday, June 16th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/ohr-pharmaceutical-inc-nasdaqohrp-given-14-00-consensus-target-price-by-brokerages.html
Ohr Pharmaceutical (NASDAQ:OHRP) traded up 2.20% during midday trading on Monday, reaching $2.79. 18,396 shares of the company’s stock were exchanged. The firm’s market capitalization is $89.57 million. Ohr Pharmaceutical has a 52 week low of $2.44 and a 52 week high of $6.56. The firm’s 50 day moving average is $2.74 and its 200 day moving average is $2.92.
Ohr Pharmaceutical (NASDAQ:OHRP) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.03. On average, equities analysts anticipate that Ohr Pharmaceutical will post ($1.32) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in shares of Ohr Pharmaceutical during the second quarter valued at $144,000. Bank of New York Mellon Corp increased its position in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock valued at $164,000 after buying an additional 757 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock valued at $206,000 after buying an additional 9,685 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Ohr Pharmaceutical by 3.9% in the first quarter. Geode Capital Management LLC now owns 152,915 shares of the company’s stock valued at $490,000 after buying an additional 5,794 shares during the last quarter. Finally, Opaleye Management Inc. acquired a new position in shares of Ohr Pharmaceutical during the first quarter valued at $1,175,000. 11.32% of the stock is owned by institutional investors and hedge funds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.